High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Inclusion Criteria: * Patient who has signed a written consent * Age ≥ 19 ③ Histologically diagnosed advanced/metastatic solid cancer * Patients who have received myelosuppressive chemotherapy for palliative purposes within 1 month of participating in the study and plan to proceed with chemotherapy while participating in this study * Anemia with functional iron deficiency 1. Hemoglobin \<10g/dL 2. functional iron deficiency: transferrin saturation \<50% AND serum ferritin 30-800ng/mL ⑤ ECOG performance status 0-2 ⑥ life expectancy ≥ 24weeks Exclusion Criteria: * Absolute iron deficiency (serum ferritin \<30 ng/mL AND transferrin saturation \<20%) or no iron deficiency (serum ferritin ≥800 ng/mL OR transferrin saturation ≥50%) * If there is another cause of anemia other than chemotherapy-induced anemia (eg, vitamin B12 or folic acid deficiency, hemolytic anemia, myelodysplastic syndrome, etc.) * Ongoing bleeding at the time of study registration * Patients who require rapid blood transfusion at the time of study registration (eg, rapidly progressing anemia) * Presence of bone marrow tumor invasion * Receiving erythropoiesis stimulating agents within 3 weeks of study registration or have a history of oral or intravenous iron administration or blood transfusion within 2 weeks of study registration * History of venous thromboembolism within 6 months or taking anticoagulants at the time of study registration * Past or family history of hemochromatosis ⑨ History of hypersensitivity to iron treatment or erythropoiesis stimulating agents ⑩ Uncontrolled acute or chronic infection ⑪ Renal dysfunction (serum creatinine ≥2.0 mg/dL, or glomerular filtration rate \<30 mL/min/1.73 m2) or liver dysfuction (AST or ALT 3 times or more the upper limit of normal) ⑫ Pregnant or lactating women